JG: Offer cloud-based analysis - track clone of interest. For blood cancers: a clonality measurement. MRD assessment too #guinformatics
11:47am October 2nd 2014 via Hootsuite
JG: Can do this from tissue, blood, or sorted T/B cells. Has a service, will soon offer a kit. Back to company for analysis #guinformatics
11:45am October 2nd 2014 via Hootsuite
JG: Details of assay: T- and B-cell receptor sequencing. V-n-D-n-J, CDR3 regions. Assay can deliver TCR and Ig CDR3 #guinformatics
11:44am October 2nd 2014 via Hootsuite
Julie Gil (Adaptive Biotechnologies, WA) "ImmunoSequencing as a potential biomarker for cancer immunotherapy" #guinformatics
11:43am October 2nd 2014 via Hootsuite
YS: Showed data from GEO, Bayesian network analysis; describes work here (PubMed) http://t.co/ie0ZLoOcbe #guinformatics
11:37am October 2nd 2014 via Hootsuite
YS: Did lit search, picked up 446 genes, defined a 53 immune gene panel in mouse predictive of non-progression #guinformatics
11:33am October 2nd 2014 via Hootsuite
YS: Primary melanoma - small tissues, entire sample is FFPE, fresh-frozen not an option. NanoString: no amplification #guinformatics
11:30am October 2nd 2014 via Hootsuite
YS: Stage II-III resectable melanoma: did the primary tumor produce micro-metastases? #guinformatics
11:27am October 2nd 2014 via Hootsuite
Yvonne Saenger (Columbia) "A 53-gene immune panel measured using the NanoString assay correlates w/ (melanoma) outcomes" #guinformatics
11:26am October 2nd 2014 via Hootsuite
JM: Found signature in 30 different cancer types, across 14.4K solid tumor samples. Implemented now on Nanostring #guinformatics
11:18am October 2nd 2014 via Hootsuite
JM: Similarly, good prognosis for melanoma. In NSCLC: no signature, no structures. Can't easily be ID visually #guinformatics
11:16am October 2nd 2014 via Hootsuite
JM: Melanoma: 120 Stage IV non-lymph node mel. metastatis, all 12 to show tumor masses. Chemokines are cause of structures #guinformatics
11:14am October 2nd 2014 via Hootsuite
JM: These structures, ID by signature, meant indiv had much better survival prognosis (CR cancer) #guinformatics
11:13am October 2nd 2014 via Hootsuite
JM: (In colorectal cancer). Now doing LCM, b/c structures recognize indiv tumors. Have shown T-cells, what abt B-cells? #guinformatics
11:12am October 2nd 2014 via Hootsuite
JM: 12 chemokines uncovered in that group; going back to the tissues, found lymphoid infiltrates (microscopic) via IHC #guinformatics
11:10am October 2nd 2014 via Hootsuite
AB: Goal - can they predict clinical response rate? 2w study: Merck grouped genes into 50 groups. One was for T cell act. #guinformatics
11:09am October 2nd 2014 via Hootsuite
JM: 443K indiv., 105K consented, 35K tumor samples, 16K expression profiles. 2K sample PCA across Ca types shown #guinformatics
11:05am October 2nd 2014 via Hootsuite
JM: Database: Oncology Research Info Exchange Network (ORIEN) - to integrate #bigdata and daa sharing for cancer res. #guinformatics
11:03am October 2nd 2014 via Hootsuite
JM: Single protocol for all sites; lifetime followup, study sample w/ molecular tech., permission to re-contact for new trial #guinformatics
11:02am October 2nd 2014 via Hootsuite
JM: M2GEN's initiative: "Total Cancer Care Initiative". 19 community hospitals. Went to places with substantial volume #guinformatics
11:01am October 2nd 2014 via Hootsuite
JM: 8y ago: Consultants for a biz plan wanted big $. A few years later: Merck $100M for development. State of FL: $60M M2GEN #guinformatics
10:59am October 2nd 2014 via Hootsuite
James Mule (Moffitt) "Platform for rapid discovery and validation of tumor immune gene-regulated signatures" #guinformatics
10:57am October 2nd 2014 via Hootsuite
MA: Panel discuss different types of biomarkers: immune sig's, mRNA via Nanostring, ImmunoSeq to ID tumor types, GWAS markers #guinformatics
10:56am October 2nd 2014 via Hootsuite
MA: The problem now is too many targets; what combinations, optimal applications of novel immunotherapies, what biomarkers #guinformatics
10:54am October 2nd 2014 via Hootsuite
MA: Points out high dose IL-2 treatment; effective for only 10%; points out Rosenberg's work for TIL + IL-2 in melanoma #guinformatics
10:49am October 2nd 2014 via Hootsuite
Michael Atkins "Cancer Immunotherapies - A journey from the wilderness to the promised land" #guinformatics
10:47am October 2nd 2014 via Hootsuite
AB:A continuum: from super high-risk, to close to commercializing. #postdocalypse is a hashtag: here's new way to do science #guinformatics
10:28am October 2nd 2014 via Hootsuite
AB:Q:New co's? A:High-risk proj not about co's. Redefined role: "I'm an idea generator" Best grants close to best biz plans #guinformatics
10:27am October 2nd 2014 via Hootsuite
AB:Q:Neurosci? A:Allen Inst., psych is ahead b/c of classification, but behind in others. 'We all have to catch up' #guinformatics
10:25am October 2nd 2014 via Hootsuite
AB: "We need more researchers doing this, using other people's data" "You can't trust that data, need to do it yourself" #guinformatics
10:24am October 2nd 2014 via Hootsuite
(Personal note: read about @atulbutte 's work before, first time hearing him well worth the effort to make it to #guinformatics today.)
10:23am October 2nd 2014 via Hootsuite
AB: #BigData in biomedicine: new drugs for diseases, dx before they occur, amazing platform for entrepreneurship #guinformatics
10:21am October 2nd 2014 via Hootsuite
AB: Showshis own child - 3rd floor of San Jose's Tech Museum, expressing GFP via a 5yo. We've got to get them comfortable #guinformatics
10:20am October 2nd 2014 via Hootsuite
AB: "Maybe kids today need to start 'garage biotechs'" #guinformatics
10:19am October 2nd 2014 via Hootsuite
AB: 'We are used to kids starting...' high-value companies. "I believe the next Amgen will start in a garage." #guinformatics
10:18am October 2nd 2014 via Hootsuite
AB: They are the first to release clinical trial data. The future. http://t.co/skOvYiXTsL #guinformatics
10:17am October 2nd 2014 via Hootsuite
(Now I notice I should be using #guinformatics, oh well!) AB: FDA regulation of mobile apps (200) #biomedical_informatics_symposium
10:16am October 2nd 2014 via Hootsuite
AB: Points out WaPo piece: difference in what hospitals charge for identical procedure. Is it quality? #biomedical_informatics_symposium
10:14am October 2nd 2014 via Hootsuite
AB: Scanadu - the tricorder idea. Indiegogo crowdfunding. $1.6M in a few days #biomedical_informatics_symposium
10:13am October 2nd 2014 via Hootsuite
AB: Theranos has transparent pricing ($3 to $17), 'I have had this done' Patients will get results fast #biomedical_informatics_symposium
10:12am October 2nd 2014 via Hootsuite
AB: Illus. Theranos, disclosed first round was $400M. Make blood testing pleasant, at Walgreens #biomedical_informatics_symposium
10:11am October 2nd 2014 via Hootsuite
AB: Showed graph of weight of himself for 20 mo. Biggest change - his Dr. knows nothing about this #biomedical_informatics_symposium
10:10am October 2nd 2014 via Hootsuite
AB: Now: Withings and fitbit: 5 people have here (~100 attending), on West Coast 'about 1/2'. #biomedical_informatics_symposium
10:09am October 2nd 2014 via Hootsuite
AB: An email from Europe entitled 'I have small cell lung cancer' "Can you help me?" #biomedical_informatics_symposium
10:08am October 2nd 2014 via Hootsuite
AB: Companies license the drug even at 'Phase -1' via computational model; how transl. occurs #biomedical_informatics_symposium
10:07am October 2nd 2014 via Hootsuite
AB: After mouse model, 15mos later a human trial has begun. So NuMedii launched. $3.5M #biomedical_informatics_symposium
10:06am October 2nd 2014 via Hootsuite
AB: Points to anti-depressant paper for small cell lung cancer 2013 PubMed http://t.co/h2OSK6OGay #biomedical_informatics_symposium
10:05am October 2nd 2014 via Hootsuite
AB: Remarkable video showing IBD in rat. 'Built for dry bench researchers' and need to learn exp'l design #biomedical_informatics_symposium
10:04am October 2nd 2014 via Hootsuite
AB: In review, asked for improved photos. A rat colonoscopy (!) video shown. (Outsourced too.) #biomedical_informatics_symposium
10:02am October 2nd 2014 via Hootsuite
AB: Doing duplicate expt, different vendor. First one, IBD using anti-seizure drug in rat model #biomedical_informatics_symposium
10:01am October 2nd 2014 via Hootsuite
